The importance of progesteron for the safety of pregnancy at early and late terms

Authors

DOI:

https://doi.org/10.18370/2309-4117.2019.48.49-54

Keywords:

micronized natural progesterone, pregnancy miscarriage, luteal phase deficiency, vaginal route of administration, progesterone, Utrogestan

Abstract

Progesterone is a key hormone to support pregnancy and pregnancy onset. Problem of low fertility, infertility is becoming increasingly important, which in turn further exacerbates miscarriage. The aim of this systematic review is to elucidate new information based on current scientific evidence, evidence-based medicine and world clinical protocols, summarize actual knowledge of the importance of sequential use of one type of gestagen for pre-conceptual preparation, treatment, and prevention of the risk of pregnancy termination in different clinical settings. Analysed data indicate that it is natural micronized progesterone to be the drug of choice in the treatment of habitual miscarriage associated with luteal phase deficiency, and it is important to use one type of gestagen at the pre-conception stage.

Currently, vaginal drugs of micronized progesterone used to support the luteal phase during IVF cycles due to the relative ease of use and efficiency equivalence to intramuscular progesterone. Vaginal progesterone has advantages due to the effect of primary passage through the uterus, it concentration in endometrial tissues is usually much higher than in serum. An independent, randomized, double-blind, placebo-controlled trial PRISM showed the efficacy of vaginal micronized progesterone in women with genital bleeding early in pregnancy (clinic of abortion). In group of micronized progesterone the rate of live birth was higher by 3% compared to placebo, which in absolute numbers was greater for 54 live births. The best results were achieved in patients with a history of 3 or more miscarriages, where the odds of live birth due to micronized progesterone (Utrogestan®) increased by 28%. Also it is important that Utrogestan® at a dose of 800 mg/day for up to 16 weeks of gestation is safe for the fetus (the frequency of congenital abnormalities did not differ in the vaginal progesterone and placebo group) and did not prevent the rejection of the genetically defective embryo.

Author Biographies

С. О. Шурпяк, Danylo Halytsky Lviv National Medical University, Lviv

MD, associate professor of the Obstetrics, Gynecology and Perinatology Department, FPE

В. І. Пирогова, Danylo Halytsky Lviv National Medical University, Lviv

MD, professor, head of the Obstetrics, Gynecology and Perinatology Department, FPE

References

  1. Nybo Andersen, A.M., Wohlfahrt, J., Christens, P., et al. “Maternal age and fetal loss: population based register linkage study.” BMJ 320 (2000): 1708–12.
  2. Sauer, M.V. “Reproduction at an advanced maternal age and maternal health.” Fertil Steril 103 (2015): 1136–43.
  3. Habbema, J.D., Eijkemans, M.J., Leridon, H., te Velde, E.R. “Realizing a desired family size: when should couples start?” Hum Reprod 30 (2015): 2215–21.
  4. Lo, W., Rai, R., Hameed, A., et al. “The effect of body mass index on the outcome of pregnancy in women with recurrent miscarriage.” J Family Community Med 19 (2012): 167–71.
  5. Bhattacharya, S., Townend, J., Bhattacharya, S. “Recurrent miscarriage: Are three miscarriages one too many? Analysis of a Scottish population-based database of 151,021 pregnancies.” Eur J Obstet Gynecol Reprod Biol 150 (2010): 24–7.
  6. Grande, M., Borrell, A., Garcia-Posada, R., et al. “The effect of maternal age on chromosomal anomaly rate and spectrum in recurrent miscarriage.” Hum Reprod 27 (2012): 3109–17.
  7. Sharma, R., Agarwal, A., Rohra, V.K., et al. “Effects of increased paternal age on sperm quality, reproductive outcome and associated epigenetic risks to offspring.” Reprod Biol Endocrinol 13 (2015): 35.
  8. Li, W., Newell-Price, J., Jones, G.L., et al. “Relationship between psychological stress and recurrent miscarriage.” Reprod Biomed Online 25 (2012): 180–9.
  9. Kolte, A.M., Olsen, L.R., Mikkelsen, E.M., et al. “Depression and emotional stress is highly prevalent among women with recurrent pregnancy loss.” Hum Reprod 30 (2015): 777–82.
  10. Nepomnaschy, P.A., Welch, K.B., McConnell, D.S., et al. “Cortisol levels and very early pregnancy loss in humans.” Proc Natl Acad Sci U S A 103 (2006): 3938–42.
  11. Nelson, D.B., Grisso, J.A., Joffe, M.M., et al. “Does stress influence early pregnancy loss?” Ann Epidemiol 13 (2003): 223–9.
  12. Plana-Ripoll, O., Parner, E., Olsen, J., Li, J. “Severe stress following bereavement during pregnancy and risk of pregnancy loss: results from a population-based cohort study.” J Epidemiol Community Health 70 (2016): 424–9.
  13. Cicinelli, E., Matteo, M., Tinelli, R., et al. “Chronic endometritis due to common bacteria is prevalent in women with recurrent miscarriage as confirmed by improved pregnancy outcome after antibiotic treatment.” Reprod Sci 21 (2014): 640–7.
  14. McQueen, D.B., Bernardi, L.A., Stephenson, M.D. “Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise.” Fertil Steril 101 (2014): 1026–30.
  15. McQueen, D.B., Perfetto, C.O., Hazard, F.K., Lathi, R.B. “Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss.” Fertil Steril 104 (2015): 927–31.
  16. Kitaya, K. “Prevalence of chronic endometritis in recurrent miscarriages.” Fertil Steril 95 (2011): 1156–8.
  17. Russell, P., Sacks, G., Tremellen, K., Gee, A. “The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. III: Further observations and reference ranges.” Pathology 45 (2013): 393–401.
  18. Bouet, P.E., El Hachem, H., Monceau, E., et al. “Chronic endometritis in women with recurrent pregnancy loss and recurrent implantation failure: prevalence and role of office hysteroscopy and immunohistochemistry in diagnosis.” Fertil Steril 105 (2016): 106–10.
  19. Lucas, E.S., Dyer, N.P., Murakami, K., et al. “Loss of Endometrial Plasticity in Recurrent Pregnancy Loss.” Stem Cells 34 (2016): 346–56.
  20. Practice Committee of the American Society for Reproductive Medicine. “Current clinical irrelevance of luteal phase deficiency: a committee opinion.” Fertil Steril 103 (2015): e27–32.
  21. Cakmak, H., Taylor, H.S. “Implantation failure: molecular mechanisms and clinical treatment.” Hum Reprod Update 17 (2011): 242–53.
  22. Simon, C., Martin, J.C., Pellicer, A. “Paracrine regulators of implantation.” Baillieres Best Pract Res Clin Obstet Gynaecol 14 (2000): 815–26.
  23. Wang, H., Dey, S.K. “Roadmap to embryo implantation: clues from mouse models.” Nat Rev Genet 7 (2006): 185–99.
  24. Dey, S.K., Lim, H., Das, S.K., et al. “Molecular cues to implantation.” Endocr Rev 25 (2004): 341–73.
  25. Maltseva, L.I., Bril, Y.A. Protocol Rules. Progesterone preparations in clinical recommendations (ed. by V. Radzinsky). Moscow. Editorial board of StatusPraesens Journal (2018).
  26. Druckmann, R., et al. “Progesterone and the immunology of pregnancy.“ J Steroid Biochem Mol Biol 97 (2005): 389–96.
  27. Szekeres-Bartho, J., et al. “Progesterone as an immunomodulatory molecule.“ Int Immunopharmacol 1 (2001): 1037–48.
  28. Fanchin, R., et al. “Hormonal influence on the uterine contractility during ovarian stimulation.“ Hum Reprod 15 (2000): 90–100.
  29. Perusquía, M., et al. “Influence of 5 alpha-and 5 beta-reduced progestins on the contractility of isolated human myometrium at term.” Life Sci 68 (2001): 2933–44.
  30. Chanrachakul, B., et al. “Progesterone enhances the tocolytic effect of ritodrine I isolated pregnant human myometrium.” Am J Obstet Gynecol 192 (2005): 458–63.
  31. Liu, J., et al. “The effects of progesterone on apoptosis in the human trophoblast-derived HTR-8/SV neo cells.” Mol Hum Reprod 13 (2007): 869–74.
  32. Czajkowski, K., et al. “Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone.” Fertil Steril 87 (2007): 613–8.
  33. Schwartz, N., et al. “Progesterone suppresses the fetal inflammatory response ex vivo.” Am J Obstet Gynecol 201 (2009): 211–9.
  34. Stephenson, M.D., McQueen, D., Winter, M., et al. “Luteal start vaginal micronized progesterone improves pregnancy success in women with recurrent pregnancy loss” Fertil Steril 107.3 (2017): 684–90.
  35. van Oppenraaij, R.H.F., et al. “Predicting adverse obstetric outcome after early pregnancy. Events and complications: a review.” Human Reproduction Update 15.4 (2009): 409–21.
  36. NICE Guideline NG 126. Ectopic pregnancy and miscarriage: diagnosis and initial management (2019).
  37. Coomarasamy, A., et al. “A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy.” N Engl J Med 380 (2019): 1815–24.
  38. MSD Manual for the Professional. Available from: [https://www.msdmanuals.com/professional/gynecology-and obstetrics], last accessed Sept 17, 2019.
  39. Ogasawara, M., et al. “Embryotic karyotype of abortuses in relation to the number of previous miscarriage.” Fertil Steril 73.2 (2000): 300–4.
  40. European Society of Human Reproduction and Embryology. Recurrent pregnancy loss Guideline of the ESHRE (2017).
  41. Field, K., Murphey, D.J. “Perinatal outcomes in a subsequent pregnancy among women who have experienced recurrent miscarriage: a retrospective cohort study.” Human Reproduction 30.5 (2015): 1239–45.
  42. FIGO Working Group on Best Practice in Maternal‐Fetal Medicine. “Best practices in maternal fetal medicine.” Int J Gynecol Obstet 128 (2015): 80–2.
  43. Coomarasamy, A., et al. “A Randomized Trial of Progesterone in Women with Recurrent Miscarriages.” N Engl J Med 373 (2015): 2141–8.
  44. Norman, J.E., et al. “Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.” Lancet 387 (2016): 2106–16.
  45. Fonseca, E.B., Celik, E., Parra, M., et al. “Progesterone and the risk of preterm birth among women with a short cervix.” N Engl J Med 357 (2007): 462–9.
  46. Hassan, S.S., Romero, R., Vidyadhari, D., et al. “Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebocontrolled trial.” Ultrasound Obstet Gynecol 38 (2011): 18–31.

Downloads

Published

2019-10-03

How to Cite

Шурпяк, С. О., & Пирогова, В. І. (2019). The importance of progesteron for the safety of pregnancy at early and late terms. REPRODUCTIVE ENDOCRINOLOGY, (48), 49–54. https://doi.org/10.18370/2309-4117.2019.48.49-54

Issue

No. 48 (2019)

Section

Pregnancy and childbirth

License

Copyright (c) 2019 С. О. Шурпяк, В. І. Пирогова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.